Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.

Abstract

Psilocybin-assisted interventions are moving from efficacy trials toward psychiatric implementation. Cardiovascular interpretation is central to this transition because trial participants are generally medically selected, receive standardized pharmaceutical-grade doses, and are monitored more intensively than many patients encountered in routine care. This review translates the cardiovascular evidence into a risk-stratified psychiatric decision framework. We conducted a structured narrative review of clinical trials, systematic reviews, meta-analyses, cardiovascular pharmacology, drug-interaction studies, product-standardization literature, and implementation guidance. Searches were updated through July 10, 2026. Evidence was selected purposively to address acute hemodynamics, corrected QT interval (QTc), 5-hydroxytryptamine receptor-mediated effects, valvular biology, repeated exposure, naturally derived product variability, and practical screening and monitoring. In supervised studies, pooled estimates indicate mean increases of approximately 19.0 mmHg in systolic blood pressure and 8.7 mmHg in diastolic blood pressure. The largest and most consistent group differences occur about 60-90 min after dosing and generally resolve within 4-6 h; heart-rate effects are smaller and less consistent. Serious acute cardiovascular events remain uncommon in selected participants. Risk interpretation changes with cardiovascular comorbidity, interacting medications, repeated exposure, and non-standardized mushroom products, whose active-alkaloid content can vary by more than an order of magnitude. Mean QTc effects at standard exposure are small. A 5-HT2B-mediated valvular concern remains biologically plausible under chronic exposure, but assay results and exposure-margin estimates are heterogeneous and clinical valvular injury has not been established. Current evidence supports monitored, intermittent administration of standardized psilocybin in carefully selected populations, not general cardiovascular reassurance across all products, exposure patterns, or psychiatric settings. Product identity, medication review, risk-stratified cardiovascular assessment, session monitoring, and explicit escalation pathways should be integrated into treatment planning.